Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Eukarÿs

Eukarÿs_logo
11
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Based on its proprietary expression system, Eukarÿs develops a radically novel, safe and efficient synthetic gene therapy for liver diseases and cancer, currently at preclinical stage, as well as high performance bioproduction systems for biologics

Evry, Île-de-France, France

Send a message

  • 3

    employees

  • €20,000

    turnover

Anglais

Eukarÿs

Anglais

Eukarÿs is deep-tech Biotech Company of the Genopole of Evry (France). We have developped a proprietary core technology with two main applications, which explains our mixed business model.

One a one hand we develop a radically innovative non-viral therapeutic approach named synthetic gene therapy, which can be used to treat most human diseases while initially focusing on the treatment of liver diseases and cancers. Synthetic gene therapy is designed as safe, non-integrative, well...

See more

Eukarÿs is deep-tech Biotech Company of the Genopole of Evry (France). We have developped a proprietary core technology with two main applications, which explains our mixed business model.

One a one hand we develop a radically innovative non-viral therapeutic approach named synthetic gene therapy, which can be used to treat most human diseases while initially focusing on the treatment of liver diseases and cancers. Synthetic gene therapy is designed as safe, non-integrative, well tolerated, self-vectorized, produced at an acceptable cost. Proof of concept of efficacy and tolerability has been obtained for our first therapy.

On the other hand, Eukarÿs also develops high performance bioproduction systems for biologics, including recombinant proteins, viruses and vaccines, and this activity should lead to the creation of an independent subsidiary maturing in 2024.

Finally, our goal is to demonstrate the effectiveness of the synthetic gene therapy in clinical studies, then to conclude a co-development agreement with Pharma in 2024. To achieve this goal and the next critical steps, our financing needs are estimated at between €18M, with current fundraising round of €300,000.

Our latest news

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
126 Entities

Communities

ESIL - Early Stage Investing Launchpad
Early Stage Investing Launchpad has the overall objective of developing and boosting the activities for Business Angels through an international capacity building program
405 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1138 Members

Our history

Start in 20/03/2010

  • 20/03/2010

    In vitro POC of our core technology - the C3P3 system - is obtained and the patent is filled

  • 26/06/2010

    Eukarÿs is founded as a SAS

  • 21/11/2011

    Eukarÿs wins i-LAB, the award from the French Ministry for Research (€450,000)

  • 21/08/2013

    C3P3-G1 patent is granted in Europe

  • 10/01/2017

    C3P3-G1 patent is granted in the USA

to be continued ...